Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Angina Pectoris Drugs Market Heading Into 2029?

In recent years, a consistent growth has been witnessed in the market size for drugs treating angina pectoris. It is anticipated to expand from $12.32 billion in 2024 to $12.88 billion in 2025, presenting a Compound Annual Growth Rate (CAGR) of 4.5%. Factors contributing to the growth during the historical period include an increase in cardiovascular diseases, aging population, lifestyle habits, along with escalated hypertension rates and widespread prevalence of diabetes.

The market for angina pectoris drugs is predicted to experience significant expansion in the coming years. The market is projected to increase to “$16.42 billion in 2029, with a compound annual growth rate (CAGR) of 6.3%. This growth during the forecast period can be attributed to factors such as an increase in global obesity rates, advancements in precision medicine, emphasis on preventive cardiology, patient education initiatives, and research on new therapeutic targets. Anticipated trends for the forecast period include the use of telemedicine for remote patient monitoring, studies on real-world evidence and outcomes, patient-focused medication education, strategic partnerships for market accessibility, advances in regulation, and fast-tracked approvals.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp

Which Factors Are Pushing The Angina Pectoris Drugs Market Forward?

The escalation in the incidences of cardiovascular disorders is projected to spur the expansion of the angina pectoris drug market. These disorders include a variety of diseases affecting the heart and circulatory system, such as high blood pressure, coronary artery disease, stroke, and heart failure. The demographic aging, unhealthy life choices, and the rise in obesity can be linked to the growing prevalence of cardiovascular diseases (CVD). Angina pectoris pharmaceuticals, including nitrates, beta-blockers, and calcium channel blockers, provide effective relief from chest pain and discomfort resulting from inadequate blood supply to the heart, thus improving patients’ general quality of life. For example, data disclosed by the British Heart Foundation in September 2024 revealed that around 7.6 million individuals suffer from heart and circulatory diseases in the UK, including approximately 4 million males and 3.6 million females. These diseases account for roughly 27% of the total deaths in the UK, equivalent to over 170,000 deaths per year, or about 480 deaths each day, which means one death every three minutes. Consequently, the rising prevalence of cardiovascular disorders is propelling the angina pectoris drug market’s growth.

Which Segment Held The Largest Share In The Angina Pectoris Drugs Market In 2025?

The angina pectoris drugs market covered in this report is segmented –

1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs

2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina

3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates

2) By Antiplatelet Agents: Aspirin, Clopidogrel

3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers

4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers

5) By Anti-Ischemic Agents: Ranolazine, Ivabradine

6) By Statins: Atorvastatin, Rosuvastatin

What Notable Trends Are Shaping The Direction Of The Angina Pectoris Drugs Market?

The angina pectoris drugs market is seeing a surge in product innovation, a trend that is increasingly becoming mainstream. Key businesses in the angina pectoris medication industry are embracing novel technologies to maintain their market stance. For instance, Hikma Pharmaceuticals PLC, a pharmaceutical enterprise based out of the UK, launched the Labetalol Hydrochloride Injection, USP, in a prefilled syringe in March 2023. This product has received approval from the United States Food and Drug Administration. It is used in hospitals for treating severe hypertension and reducing high blood pressure, typically administered as a 10 mg/2 mL PFS.

Which Organizations Are Driving Progress In The Angina Pectoris Drugs Industry?

Major companies operating in the angina pectoris drugs market include Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AERIE PHARMACEUTICALS INC., AbbVie Inc., Amgen Inc., Gilead Sciences Inc., GlaxoSmithKline plc, H. Lundbeck A/S, Ipsen S.A., Lupin Pharmaceuticals Inc., Merck KGaA, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Servier Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Angina Pectoris Drugs Industry?

North America was the largest region in the angina pectoris drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10797&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model